Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, The First Dongguan Affiliated Hospital, College of Medical Technology, Guangdong Medical University, Dongguan, 523808, China.
College of Pharmacy, Guangdong Medical University, Dongguan, 523808, China.
Respir Res. 2024 Aug 17;25(1):311. doi: 10.1186/s12931-024-02947-3.
Tea polyphenols (TPs), prominent constituents of green tea, possess remarkable antioxidant and anti-inflammatory properties. However, their therapeutic potential is limited due to low absorption and poor bioavailability. To address this limitation and enhance their efficacy, we developed a biomimetic nanoplatform by coating platelet membrane (PM) onto poly-lactic-co-glycolic acid (PLGA) nanoparticles (NPs) to create targeted delivery vehicles for TPs (PM@TP/NPs) to the inflamed tissues in asthma.
After synthesizing and characterizing PM@TP/NPs, we assessed their biocompatibility and biosafety through cell viability assays, hemolysis tests, and inflammation analysis in vivo and in vitro. The therapeutic effect of PM@TP/NPs on asthma was then evaluated using a mouse model of HDM-induced asthma. Additionally, PM@TP/NPs-mediated reactive oxygen species (ROS) scavenging capacity, as well as the activation of signaling pathways, were analyzed in HBE cells and asthmatic mice via flow cytometry, RT-qPCR, and western blotting.
Compared with free TPs, PM@TP/NPs demonstrated excellent biocompatibility and safety profiles in both in vitro and in vivo, as well as enhanced retention in inflamed lungs. In HDM-induced mouse asthma model, inhaled PM@TP/NPs largely attenuated lung inflammation and reduced the secretion of type 2 pro-inflammatory cytokines in the lungs compared to free TPs. The therapeutic effects of PM@TP/NPs on asthma might be associated with an enhanced ROS scavenging capacity, increased activation of the Nrf2/HO-1 pathway, and decreased activation of the CCL2/MAPK and TLR4/NF-κB pathway in the lungs.
Our findings demonstrate that inhalation of PM@TP/NPs largely attenuated lung inflammation in HDM-induced asthmatic mice. These results suggest that PM@TP/NPs might be a novel therapeutic strategy for asthma.
茶多酚(TPs)是绿茶的主要成分,具有显著的抗氧化和抗炎特性。然而,由于其吸收不良和生物利用度低,其治疗潜力受到限制。为了解决这个限制并提高其疗效,我们通过将血小板膜(PM)涂覆在聚乳酸-羟基乙酸共聚物(PLGA)纳米颗粒(NPs)上来开发仿生纳米平台,以创建针对哮喘中炎症组织的 TPs 的靶向递送载体(PM@TP/NPs)。
合成并表征 PM@TP/NPs 后,我们通过细胞活力测定、溶血试验以及体内和体外炎症分析来评估其生物相容性和生物安全性。然后使用 HDM 诱导的哮喘小鼠模型评估 PM@TP/NPs 对哮喘的治疗效果。此外,通过流式细胞术、RT-qPCR 和 Western blot 分析 PM@TP/NPs 在 HBE 细胞和哮喘小鼠中对活性氧(ROS)的清除能力以及信号通路的激活。
与游离 TPs 相比,PM@TP/NPs 在体内和体外均表现出优异的生物相容性和安全性,并且在炎症肺部中的保留时间更长。在 HDM 诱导的小鼠哮喘模型中,与游离 TPs 相比,吸入 PM@TP/NPs 可大大减轻肺部炎症并减少肺部 2 型促炎细胞因子的分泌。PM@TP/NPs 对哮喘的治疗作用可能与增强的 ROS 清除能力、增加 Nrf2/HO-1 通路的激活以及减少肺部 CCL2/MAPK 和 TLR4/NF-κB 通路的激活有关。
我们的研究结果表明,吸入 PM@TP/NPs 可大大减轻 HDM 诱导的哮喘小鼠肺部炎症。这些结果表明,PM@TP/NPs 可能是治疗哮喘的一种新的治疗策略。